U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C23H21F6NO3
Molecular Weight 473.4082
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CI-966 FREE BASE

SMILES

OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)C1

InChI

InChIKey=CMHQDSBIBSKHFP-UHFFFAOYSA-N
InChI=1S/C23H21F6NO3/c24-22(25,26)18-7-3-15(4-8-18)20(16-5-9-19(10-6-16)23(27,28)29)33-13-12-30-11-1-2-17(14-30)21(31)32/h2-10,20H,1,11-14H2,(H,31,32)

HIDE SMILES / InChI

Molecular Formula C23H21F6NO3
Molecular Weight 473.4082
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

CI-966 is a GABA reuptake inhibitor, acting as an indirect and nonselective GABA agonist by blocking GABA transporter protein GAT-1. CI-966 was investigated in phase I clinical study for treatment of epilepsy, but its development was discontinued due to physical and mental disturbances at high doses.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.26 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
0.28 μg/mL
10 mg single, oral
CI-966 plasma
Homo sapiens
0.09 μg/mL
5 mg single, oral
CI-966 plasma
Homo sapiens
0.5 μg/mL
25 mg single, oral
CI-966 plasma
Homo sapiens
1.2 μg/mL
50 mg single, oral
CI-966 plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4.66 μg × h/mL
10 mg single, oral
CI-966 plasma
Homo sapiens
2.8 μg × h/mL
5 mg single, oral
CI-966 plasma
Homo sapiens
13.6 μg × h/mL
25 mg single, oral
CI-966 plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
12.2 h
10 mg single, oral
CI-966 plasma
Homo sapiens
20.2 h
5 mg single, oral
CI-966 plasma
Homo sapiens
21.4 h
25 mg single, oral
CI-966 plasma
Homo sapiens
15.7 h
50 mg single, oral
CI-966 plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
In phase 1 clinical trial CI-966 was administered orally. Doses 1-10 mg were well tolerated. A volunteer who received 25 mg of CI-966 developed transient short- and long-term memory deficits. Both volunteers following administration of 50 mg drug doses presented with a constellation of physical and mental disturbances.
Route of Administration: Oral
In Vitro Use Guide
The ability of CI-966 to block GABA transport was measured using human cells, stably transfected with GAT-1 transporter. Cells were grown in 25 well plates, washed with Hepes-buffered saline and allowed to equilibrate at 37°C for 10 min. The medium was removed and the drug was added. Transport was initiated by adding 50 uL of a concentrated [3H]GABA solution at a final concentration of 50 nM. Plates were incubated for 10 min, then washed, solubilized, and radioactivity was determined by scintillation counting. CI-966 inhibited [3H]GABA transport with IC50 of 0.26 uM.
Substance Class Chemical
Record UNII
4HVE799MEJ
Record Status Validated (UNII)
Record Version